The invention relates to a food supplement containing minerals and/or vitamins, a humectant and, for example, essential oils. The food supplement is formulated as an oral spray. In particular, the invention relates to a concentrated food supplement in the form of an oral spray, containing a combination of magnesium ions, panthenol (vitamin B5), caffeine, menthol aroma and/or peppermint aroma, and a humectant. The food supplement is particularly suited for use in sport and in stressful situations.

Novel process and products thereby emplace NSAIDS within nanodelivery vehicles for various indications in mammals, including humans.

In certain embodiments a dental strip for the prevention or reduction of dental caries is provided. In certain embodiments the dental strip is constructed to deliver effective amounts of specifically targeted antimicrobial peptides (or simple antimicrobial peptides) and comprises an orally compatible backing layer, a delivery layer disposed on one surface of the backing layer where the delivery layer comprises an orally compatible polymer, or combination of polymers, and a specifically targeted antimicrobial peptide (and/or simple antimicrobial peptide) capable of binding and killing Streptococcus mutans. In certain embodiments the dental strip additionally comprises a release liner.

Homeopathic spray, gel, and rinse compositions containing tinctures of Arnica montana, Calendula officinalis, Chamomilla, Ignatia amara, Echinacea purpurea and/or Echinacea angustifolia are disclosed, along with homeopathic compositions containing tinctures of Calendula officinalis, Echinacea purpurea, Plantago major, and Azadirachta indica. Methods of using, and kits containing, the homeopathic spray, gel, rinse and other compositions for maintaining oral care and reducing inflammation, pain, and bruising after oral surgery are provided.

The invention relates to a kit of parts comprising N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and harmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also provided is a composition comprising N,N-dimethyltryptamine fumarate and harmine hydrochloride. Further, the invention relates to a pharmaceutical composition comprising N,N-dimethyltryptamine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; and harmine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The invention relates to a composition containing catechins found in green tea, to pharmaceutical compositions and medical devices comprising the composition and to the use of these compositions and medical devices in the treatment of coronavirus infections, especially infection with SARS-CoV-2.

The present disclosure relates to an oral eliglustat transmucosal delivery system. More specifically, the present disclosure is related to an oral transmucosal dosage form comprising a non-disintegrating solid mass comprising (a) a hydrophilic viscosity modifying agent selected from a natural or a synthetic gum with a molecular weight of 10,000 Daltons or greater, (b) a low molecular weight water soluble component with a molecular weight of less than 10,000 Daltons and (c) not more than 70 mg eliglustat, wherein the dosage form is 500 mg or less and provides an oral cavity residence time of at least about 5 minutes, and wherein the dosage form generates a microenvironment inside the oral cavity exhibiting a thixotropic behavior with viscosities of at least 50 poises at 1/sec shear rate and at least 10 poises at 10/sec share rate. The dosage forms of as described herein have at least 30% dose reduction as compared to commercially available eliglustat capsules. In addition, unlike the dosing prerequisite for commercially available eliglustat capsules, the oral eliglustat transmucosal dosage form described herein can be administered to patients with Gaucher disease type 1 without pre-determination of patients' CYP2D6 genotype.

The present disclosure relates generally to stapled peptides, and pharmaceutical compositions thereof, which are useful for preventing and/or treating herpes simplex virus-1 (HSV-1) processive DNA synthesis, propagation, and/or infection in a subject. The present disclosure further provides methods for treating herpes simplex keratitis in a subject

Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.

##STR00001##

Disclosed herein are orally acceptable topical analgesic gels comprising a mixture of herbal oils and extracts comprising (a) clove oil and/or eugenol (e.g., clove leaf oil and/or clove bud oil), (b) a cooling agent (e.g., menthol), (c) camphor, (d) an antimicrobial agent, e.g., turmeric and/or curcumin extract (e.g., turmeric, white turmeric (e.g., white curcumin) and (e) licorice; in an orally acceptable gel base, the gel base comprising one or more nonionic surfactants, the formulation providing a sustained release of the mixture of herbal oils and extracts following application to a tooth or gums; together with methods of making and using the same.